Clinical Trial Update: A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor [NA]

View source ↗

Summary

Apatinib plus letrozole, with or without fluzoparib, are being studied for estrogen receptor-positive, platinum-sensitive recurrent ovarian cancer previously tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluzoparib (fluzoparib)
• Letrozole (letrozole)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Ovarian Cancer | NA | Status: TERMINATED